John Hunter Peel Alexander, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 2400 Pratt St, Durham, NC 27705
Phone (919) 668-8955
Email address john.h.alexander@duke.edu

John H. Alexander, MD, MHS is a cardiologist and Professor of Medicine in the Department of Medicine, Division of Cardiology at Duke University School of Medicine, as well as the Vice Chief, Clinical Research in the Division of Cardiology. He is the Director of Cardiovascular Research at the Duke Clinical Research Institute where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and observational clinical research programs. He is a member of the American Society of Clinical Investigation.

Dr. Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research is focused on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes, chronic coronary artery disease, and cardiac surgery and on novel methodological approaches to clinical trials. He was on the Executive Committee of the ARISTOTLE trial of apixaban in patients with atrial fibrillation and was the Principal Investigator of the APPRAISE-2 trial of apixaban in patients with acute coronary syndromes.

Dr. Alexander has published extensively and has served as the principal investigator of numerous multicenter clinical trials. He currently serves as the co-chair of the Clinical Trial Transformation Initiative (CTTI).

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 1996 - 2000
  • Medical Resident, Medicine, Children's Hospital Boston, 1993 - 1996
  • M.D., University of Pennsylvania, 1993

Publications

Curtis, JP, Alexander, JH, Huang, Y, Wallentin, L, Verheugt, FWA, Armstrong, PW, Krumholz, HM, Van de Werf, F, Danays, T, Cheeks, M, Granger, CB, and ASSENT-2 and ASSENT-3 Investigators, . "Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3)." Am J Cardiol 94, no. 3 (August 1, 2004): 279-283.

PMID
15276088
Full Text

Waters, RE, Singh, KP, Roe, MT, Lotfi, M, Sketch, MH, Mahaffey, KW, Newby, LK, Alexander, JH, Harrington, RA, Califf, RM, and Granger, CB. "Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction." Journal of the American College of Cardiology 43, no. 12 (June 2004): 2153-2159. (Review)

PMID
15193673
Full Text

Sinnaeve, PR, Alexander, JH, Bogaerts, K, Belmans, A, Wallentin, L, Armstrong, P, Adgey, JAA, Tendera, M, Diaz, R, Soares-Piegas, L, Vahanian, A, Granger, CB, and Van De Werf, FJ. "Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction." Am Heart J 147, no. 6 (June 2004): 993-998.

PMID
15199346
Full Text

Alexander, JH, Peterson, ED, Chen, AY, Harding, TM, Adams, DB, and Kisslo, JA. "Feasibility of point-of-care echocardiography by internal medicine house staff." American Heart Journal 147, no. 3 (March 2004): 476-481.

PMID
14999197
Full Text

Roe, MT, Mahaffey, KW, Kilaru, R, Alexander, JH, Akkerhuis, KM, Simoons, ML, Harrington, RA, Tardiff, BE, Granger, CB, Ohman, EM, Moliterno, DJ, Lincoff, AM, Armstrong, PW, Van de Werf, F, Califf, RM, and Topol, EJ. "Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes." European Heart Journal 25, no. 4 (February 2004): 313-321.

PMID
14984920
Full Text

Alexander, JH. "Clinical trials in Japan and the United States." Am Heart J 147, no. 2 (February 2004): 200-201.

PMID
14760313
Full Text

Alexander, JH, Dyke, CK, Yang, H, Becker, RC, Hasselblad, V, Zillman, LA, Kleiman, NS, Hochman, JS, Berger, PB, Cohen, EA, Lincoff, AM, Saint-Jacques, H, Chetcuti, S, Burton, JR, Buergler, JM, Spence, FP, Shimoto, Y, Robertson, TL, Kunitada, S, Bovill, EG, Armstrong, PW, Harrington, RA, and XaNADU-PCI PILOT Investigators, . "Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot." J Thromb Haemost 2, no. 2 (February 2004): 234-241.

PMID
14995984
Scholars@Duke

Rebeiz, AG, Roe, MT, Alexander, JH, Mahaffey, KW, Granger, CB, Peterson, ED, Califf, RM, and Harrington, RA. "Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes." The American Journal of Medicine 116, no. 2 (January 2004): 119-129. (Review)

PMID
14715326
Full Text

Becker, RC, Alexander, J, Li, YF, Bovill, E, Spencer, FA, Robertson, TL, Kunitada, S, Dyke, CK, and Harrington, RA. "Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - A direct and selective antagonist [1]." Thrombosis and Haemostasis 92, no. 6 (2004): 1229-1231.

PMID
15622616
Scholars@Duke

Alexander, JH, Harrington, RA, Bhapkar, M, Mahaffey, KW, Lincoff, AM, Ohman, EM, Klootwijk, P, Pahlm, O, Henden, B, Deckers, JW, Simoons, ML, Califf, RM, and Wagner, GS. "Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes." The American Journal of Medicine 115, no. 8 (December 2003): 613-619.

PMID
14656613
Full Text

Pages